United Therapeutics (NASDAQ:UTHR) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

United Therapeutics (NASDAQ:UTHR) had its price objective raised by stock analysts at Royal Bank Of Canada from $697.00 to $725.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Royal Bank Of Canada‘s target price suggests a potential upside of 27.35% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. decreased their price objective on shares of United Therapeutics from $710.00 to $695.00 and set an “overweight” rating on the stock in a research report on Wednesday, October 28th. Bank of America reduced their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. UBS Group set a $725.00 price objective on shares of United Therapeutics in a report on Monday, October 19th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $728.00 price objective on shares of United Therapeutics in a research note on Wednesday, October 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $850.00 price objective on shares of United Therapeutics in a research note on Monday, October 26th. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $673.73.

United Therapeutics Stock Performance

United Therapeutics stock traded down $39.21 during midday trading on Thursday, hitting $569.28. 350,209 shares of the company’s stock were exchanged, compared to its average volume of 556,257. The company has a market cap of $24.42 billion, a P/E ratio of 20.39, a PEG ratio of 4.35 and a beta of 0.49. The stock has a 50-day moving average price of $532.33 and a two-hundred day moving average price of $532.45. United Therapeutics has a 52-week low of $444.04 and a 52-week high of $614.23.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share for the quarter, missing the consensus estimate of $6.01 by ($0.30). The business had revenue of $832.50 million during the quarter, compared to analysts’ expectations of $781.14 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the business earned $7.16 EPS. As a group, sell-side analysts expect that United Therapeutics will post 26.09 earnings per share for the current year.

United Therapeutics declared that its Board of Directors has approved a share buyback program on Thursday, October 22nd that authorizes the company to buy back $2 billion in shares. This repurchase authorization authorizes the biotechnology company to purchase up to 8.3% of its stock through open market purchases. Share repurchase programs are usually a sign that the company’s board believes its stock is undervalued.

Insider Activity at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $596.22, for a total value of $5,664,090.00. Following the transaction, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at $193,439,405.46. The trade was a 2.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $544.30, for a total transaction of $4,517,690.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $24,587,119.60. The trade was a 15.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 393,228 shares of company stock valued at $207,340,321 in the last quarter. Corporate insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Arjuna Capital raised its stake in shares of United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after acquiring an additional 18 shares during the last quarter. Abacus Wealth Partners LLC boosted its holdings in shares of United Therapeutics by 5.6% during the third quarter. Abacus Wealth Partners LLC now owns 396 shares of the biotechnology company’s stock worth $215,000 after purchasing an additional 21 shares during the period. Bryn Mawr Trust Advisors LLC grew its stake in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after purchasing an additional 24 shares during the last quarter. Parallel Advisors LLC grew its stake in shares of United Therapeutics by 2.1% in the third quarter. Parallel Advisors LLC now owns 1,154 shares of the biotechnology company’s stock worth $625,000 after purchasing an additional 24 shares during the last quarter. Finally, Meeder Advisory Services Inc. grew its stake in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after purchasing an additional 26 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: BTIG maintained its Buy rating and raised its price target to $768 from $728, citing strong momentum for Tyvaso. Article: United Therapeutics: Buy Rating, Strong Tyvaso Momentum and Higher $768 Price Target
• Positive Sentiment: Third-quarter revenue rose 4.1% year over year to $832.5 million, topping analyst expectations of about $781 million. The company also described a stronger growth outlook on its earnings call. Article: United Therapeutics Corporation Reports Third Quarter 2026 Financial Results
• Neutral Sentiment: United Therapeutics announced a buydown of a royalty tied to its investigational pulmonary arterial hypertension therapy ralinepag. The potential impact depends on the deal’s cost and the therapy’s commercial prospects. Article: United Therapeutics Announces Buydown of Ralinepag Royalty
• Negative Sentiment: Adjusted earnings per share of $5.71 missed the roughly $6.01 consensus and fell from $7.16 a year earlier. The earnings shortfall, despite the revenue beat, is a likely source of selling pressure. Article: United Therapeutics Q3 Earnings Miss Estimates

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.